Skip to main content

Tubulointerstitial nephritis and uveitis syndrome following meningitis and systemic lymphadenopathy with persistent Toxoplasma immunoglobulin M: a case report



Tubulointerstitial nephritis and uveitis syndrome is a rare lymphocyte-related oculorenal inflammatory disease presumed to be associated with drug use and infectious agents. Toxoplasma gondii is one of such pathogens that could exhibit encephalitis, meningitis, and uveitis in immunocompromised or in some immunocompetent individuals. If the immunoglobulin M of Toxoplasma is positive on screening, the interpretation of the result is not simple, especially when immunoglobulin M stays positive persistently.

Case presentation

A 34-year-old Asian male developed fever, headache, and lymphadenopathy with tenderness, which was initially diagnosed as meningitis. Antibiotics were started, and diclofenac sodium was used for the fever. Although his symptoms were alleviated in a week by the treatment, gradual decline in renal function was noted, prompting a renal biopsy that indicated acute granulomatous interstitial nephritis. A week later, tenderness in both eyes with blurred vision appeared and revealed iritis and keratic precipitations in both eyes; hence, the diagnosis of acute tubulointerstitial nephritis and bilateral uveitis syndrome was made. Toxoplasma gondii-specific immunoglobulin G and immunoglobulin M titers were both positive. Although we could not rule out recent infection of Toxoplasma gondii, which may cause uveitis initially, Toxoplasma immunoglobulin G avidity test indicated a distant infection, which allowed us to rule out meningitis and uveitis as responsible for the complication of recent Toxoplasma gondii infection. Drug-induced lymphocyte stimulation test, or lymphocyte transformation test of diclofenac sodium, was solely positive among the tested drugs. Uveitis was alleviated only with ophthalmic steroid, and renal function returned to normal without administration of systemic steroid.


We experienced a case of diclofenac-induced tubulointerstitial nephritis and uveitis syndrome. In ruling out infections, Toxoplasma immunoglobulin M was persistently positive, and Toxoplasma immunoglobulin G avidity test indicated a “distant” infection. From these two results, we ruled out recent infection. However, it should be noted that “distant” infection indicated by commercial immunoglobulin G avidity is still a multiplex profile consisting of reinfection, reactivation, and latent infection. Narrowing down the infection profile of Toxoplasma is challenging in some cases. Therefore, careful diagnosis and extended follow-up of such patients are needed.

Peer Review reports


Tubulointerstitial nephritis and uveitis (TINU) syndrome is a rare oculorenal multisystemic autoimmune disease that may occur in response to various environmental triggers, including drugs and microbial pathogens [1]. Since TINU syndrome was first described by Dobrin in 1975 [2], only about 200 cases have been recorded until 2018 [1]. Matsumoto has identified a total of 102 Japanese cases from literature in the period between 1977 and 2013 [3]. Patients with TINU syndrome can present with systemic symptoms (fever, fatigue, malaise, asthenia, or headache), uveitis (bilateral eye pain, redness, blurred vision, or photophobia), and tubulointerstitial nephritis (rise in serum creatinine and urinary protein). Noncaseating granulomata were found in 13% of renal biopsy specimen [4].

Toxoplasma gondii is an intracellular protozoan parasite with worldwide distribution that infects more than one-third of the global population [5]. The clinical presentation of this parasite varies from asymptomatic in healthy individuals to neurological symptoms (encephalitis [6], meningitis), ocular symptoms (uveitis, such as posterior uveitis) [6, 7], myocarditis, pneumonitis, or opportunistic infections mostly in immunocompromised hosts. Although the renal manifestation of Toxoplasma infection is not frequent [8,9,10], Toxoplasma infection is listed as a differential diagnosis of acute tubulointerstitial nephritis (TIN) [11] or of granulomatous interstitial nephritis [10]. Even in immunocompetent hosts, some (10–15%) [12,13,14,15] individuals develop acute systemic manifestations. Most frequent symptoms are lymph node enlargement (94.6%), asthenia (86.5%), headache (70.3%), and fever (67.6%). Retinochoroiditis (10.8%) is also present in the analysis of 37 immunocompetent adults with acute acquired toxoplasmosis [16]. The severity of subacute toxoplasmosis of the primary infection may vary depending on the virulence of the strain or the amount of inoculum [17]. Although most of the symptoms in immunocompetent adults are self-limited and last from a few weeks to months [16, 18], life-threatening pneumonia or death has also been reported [19].

The prevalence of recent infection of Toxoplasma in immunocompetent adults is best studied with pregnant women. Primary infection at early pregnancy is well known to cause congenital toxoplasmosis. The positive rate of both immunoglobulin G (IgG) and immunoglobulin M (IgM) specific to Toxoplasma gondii in pregnant women varies worldwide: New Zealand, South Korea, USA 0.1–0.5%, Japan 1.0–1.5% [20, 21], or 3.8% [22], Africa, and Eastern Mediterranean 2–5% [21]. To make matters more complicated, Toxoplasma IgM can persist for several months [23,24,25,26,27] or years [28] after the acute phase of primary infection (recent infection). Toxoplasma IgG avidity test is a key tool to distinguish “true” recent infection from distant infection, widely used for the screening of pregnant women. Among the initially screened IgM-positive pregnant women, as much as 59% (in Brazil) [29], 56% (in Turkey) [30], and 71.4% (in Japan) [31, 32] of them are reported to have a higher titer of IgG avidity, indicating distant infections of more than 5 months before [33]. This high frequency of persistent IgM in the initially screened IgM-positive population is one of the reasons for the lack of reliability in serological tests of Toxoplasma [34].

In the diagnosis of an autoimmune disease, differential diagnosis of dozens of systemic diseases including infections are required. Some infections are difficult to exclude because of symptoms similar to a suspected autoimmune disease. A combination of TINU syndrome and Toxoplasma gondii infection is one of them. If the IgM of Toxoplasma-specific antibody is present, the diagnostic processes become more challenging. Such cases might be misdiagnosed as TINU syndrome with coexisting active toxoplasmosis, or underdiagnosed as just toxoplasmosis. Differential diagnosis of TINU syndrome and interpretations of Toxoplasma serological tests in immunocompetent hosts will be discussed. The chances of encountering this combination might not be so rare considering the worldwide prevalence of Toxoplasma gondii.

Case presentation

A 34-year-old Japanese male with a medical history of gastric ulcer for 20 years, regular use of esomeprazole for the last 3 years, no known allergies, and no family history of kidney or eye disease presented to his local emergency department with complaints of having 2 days of 40 ℃ fever, headache, myalgia, general fatigue, and vomiting. These symptoms developed 2 days after an incised finger wound with a small amount of bleeding due to an injury during his sewage plumber work. A rapid test for influenza A and B antigens was negative; owing to concern for bacterial infection, he was started on amoxicillin and ibuprofen. His symptoms did not improve for 5 days, and he was referred to the neurology department of another hospital on day 6 of illness. On admission, he was alert. The headache and neck pain were triggered by his movement. His temperature was 38.5 °C, heart rate 88 beats/minute, and blood pressure 133/69 mmHg. Although the finger exhibited no redness, swelling, or abscess formation, physical examination revealed bilateral cervical and inguinal lymphadenopathy with tenderness. As meningeal irritation signs, neck stiffness was positive, and Kernig sign was positive at 60 degrees. No other neurological deficits were noted. White blood cell (WBC) count was 8200/mm3, with 70% neutrophils, 12.5% lymphocytes, 6.0% eosinophils, and 9.3% monocytes. Serum creatinine (Cre) was 0.91 mg/dL (80 μmol/L), and blood urea was 6.0 mg/dL (2.1 mmol/L). Erythrocyte sedimentation rate was 55 mm/hour, and serum C-reactive protein (CRP) was 11.58 mg/dL. Urine was negative for glucose and protein, the sediment contained < 1 white cell and < 1 red cell per high-power field, and two blood cultures were negative. Computed tomography (CT) scan of the brain did not identify any source of fever. A lumbar puncture was also performed in the neurology department. His cerebrospinal fluid (CSF) was clear and colorless. Initial pressure was high at 235 mmH2O. CSF cell count was 1 × 106 cells/L (1/μL) without red blood cells, glucose level was 3.66 mmol/L (66 mg/dL) [plasma glucose level 5.55 mmol/L (100 mg/dL)], and protein level was 0.31 g/L (31 mg/dL); no organisms were observed on Gram stain. No bacterial growth was detected in bottles of CSF and in bottles of blood. Then, treatment with oral levofloxacin 500 mg/day was initiated on day 6 of illness. Nonsteroidal antiinflammatory agents/drugs (NSAIDs), that is, diclofenac sodium suppositories 25 mg, were also administered three times a day for a week until remission of high fever on day 13 of illness (Fig. 2c). After the initiation of the treatment, contrary to the improvement of the inflammatory findings and parameters, kidney function deteriorated. Serum CRP levels were 11.58, 9.01, and 0.67 mg/dL, and serum Cre levels were 0.98, 1.28, and 2.74 mg/dL on day 6, 9, and 17 of illness, respectively. WBC count was 10,600/mm3, with mild elevated 12.5% eosinophil (reference value < 6.0%) on day 11. There was no skin eruption on extremities. Levofloxacin and esomeprazole were discontinued on day 17, and rapid reduction of kidney function prompted a transfer to our hospital on day 20 of illness for further evaluation and management (Fig. 2a,b). On admission, he had no fever and no complaints. There was no weight increase or pretibial pitting edema. The finger cut had healed without any scars or redness, and bilateral cervical and inguinal lymphadenopathy had diminished with little tenderness. Laboratory studies showed a WBC count of 10,000/mm3, with 60% neutrophil, 25% lymphocytes, 8.0% eosinophils, and 4.0% monocytes. Erythrocyte sedimentation rate was 22 mm/hour, serum CRP was 0.85 mg/dL, serum Cre was 2.09 mg/dL (185 umol/L), blood urea was 27.3 mg/dL (9.4 mmol/L), serum beta-2-microglobulin was 3.8 mg/L (reference value < 2.0 mg/L), urinary beta-2-microglobulin was 1589 ug/L (reference value < 229 ug/L), and urinary N-acetyl-β-d-glucosaminidase (NAG) was 7.9 IU/L (reference value < 6.9 IU/L). The results of laboratory tests showed that the levels of sodium, potassium, chloride, calcium, total protein, albumin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and uric acid were normal. IgG was 1073 mg/dL, immunoglobulin A (IgA) was 129 mg/dL, and IgM was 78 mg/dL. Urine remained negative for glucose and protein, and the sediment contained 0–1 white cell and 0–1 red cell per high-power field. Serum cystatin C measurement was 1.79 mg/L (reference value 0.57–1.01 mg/L), and glomerular filtration rate (GFR) was 61 mL/min/m2. His fractional excretion of sodium (FeNa) was elevated to 2.1% (reference value < 1%). Renal sonography revealed normal level in resistance index.

A percutaneous renal biopsy performed on day 22 of illness revealed focal or belt-like distribution of numerous mononuclear cell infiltrates in the interstitium, associated with focal tubular atrophy, tubulointerstitial edema, and mild tubulitis. The moderate diffuse interstitial inflammation was composed of lymphocytes and eosinophils with mild fibrosis (Fig. 1b). Four interstitial granulomas composed of lymphocyte, plasma cell, macrophage, epithelioid cells, and multinucleated giant cells were identified (Fig. 1a). Glomerular and vascular structures were well preserved. Immunofluorescence showed no evidence of IgG, IgA, IgM, or immune complex deposition. Acid-fast staining for Mycobacterium was negative, and Grocott staining for detection of fungi was also negative. Angiotensin-converting enzyme (ACE) level was normal (11.4 U/L) (reference value 8.3–21.4 U/L). Chest X-ray and computed tomography did not reveal any abnormal masses, or mediastinum or hilar lymphadenopathy in the lung. Gallium scintigraphy did not show any abnormal accumulations. Saxon test results were normal (5.10 g/2 minutes) (reference value > 2.00 g/2 minutes). Anti-neutrophil cytoplasmic antibody (ANCA), MPO-ANCA, PR3-ANCA, anti-nuclear antibody (ANA), anti-SS-A/SS-B, anti-beta-2GPI, anti-RNP, anti-Sm, anti-dsDNA, anti-ssDNA, anti-Scl70, and anti-glomerular basement membrane (anti-GBM) antibodies were negative. IgG4 was at a normal level, soluble IL-2 receptor was 1050 U/mL (reference value 157–474 U/mL), and IgG-, IgA-, and IgM-specific antibodies against Chlamydia did not indicate a recent infection. Serologies for human immunodeficiency viruses (HIVs) 1 and 2, hepatitis B, and hepatitis C were negative. Anti-Treponema pallidum was negative, Epstein–Barr (EBV), mumps, and cytomegalovirus (CMV) serologies were not compatible with acute infection. According to these findings, we diagnosed the patient with granulomatous interstitial nephritis.

Fig. 1

Renal biopsy. a Light microscopy of the renal biopsy (periodic acid–Schiff stain) revealed normal glomerulus with formation of interstitial granulomas indicated by arrow heads. Granulomas were composed of lymphocytes, plasma cells, macrophages, epithelioid cells, and multinucleated giant cells. Bar = 100 μm. b Magnified picture of marked area in a, revealing a focal distribution of mononuclear cell infiltrates in the interstitium, associated with focal tubular atrophy, with tubulointerstitial edema as indicated by black arrow head, and with mild tubulitis with intraepithelial lymphocytes, as indicated by white arrow heads. The moderate diffuse interstitial inflammation is composed of lymphocytes and eosinophils. Bar = 50 μm

On day 29 of illness, eye pain, conjunctival hyperemia, tenderness, photophobia, and blurred vision appeared in both eyes. Best-corrected visual acuity (BCVA) was 1.2 in the right eye and 1.5 in the left eye. Intraocular pressures were normal (right 11 mmHg/left 14 mmHg) with deep anterior chamber. Slit-lamp examination revealed iritis and keratic precipitation (corneal endothelial inflammatory precipitates/deposits) in both eyes. Anterior chamber cells were 1+ right and 0.5+ left. Dilated fundoscopic examination revealed that retina and vitreous body had nonspecific findings. No fever and no lymphadenopathy were observed. Hence, the diagnosis of acute tubulointerstitial nephritis and bilateral uveitis (TINU) syndrome was made, and ophthalmic steroid therapy was initiated (Fig. 2b, c). Symptoms of uveitis, eye pain, redness, and blurred vision disappeared in 1 week. Keratic precipitations were reduced in 1 week, and disappeared in 2 weeks. His serum Cre level gradually improved to 1.29 mg/dL on day 44 of illness without any systemic medical interventions, and systemic steroid therapy was not provided throughout the course of the disease. Mild elevation of eosinophils was also gradually improved. Percentage of peripheral eosinophils/total WBC count were 8.0%/10000, 11.6 %/6700, and 5.0%/7600 on day 20, 24, and 44 of illness, respectively.

Fig. 2.

Summary of clinical course. a: Symptoms related to meningitis are shown. CRP levels are shown in the line chart. The x-axis shows day of illness (nonlinear scale). Onset of fever is defined as day 0 of illness. Key days are shown in the bottom line; day 6: initiation of diclofenac sodium; day 17: peak day of serum Cre (red line); day 29: development of uveitis (blue line); day 44: date of discharge; day 71: restart of esomeprazole; day 239: second sampling of IgG avidity test. The same time scale is shared by a, b, c, and d. b: Symptoms related to TIN and uveitis are shown. Serum Cre and percent peripheral eosinophils of the total WBC counts (eosinophils %) are shown in the line chart. : Renal biopsy was performed on day 22 of illness. c Duration of each administered drug is shown with rectangles. The patient had been administered esomeprazole for 3 years on day 0. The results of lymphocyte transformation test (LTT)/drug-induced lymphocyte stimulation test (DLST) (performed on day 37 of illness) are shown in parenthesis on the right side. The drug positive for LTT/ DLST is shown in bold line. d Values of Toxoplasma gondii-specific IgG, IgM, and IgG avidity along with the clinical course are shown in a table. The positions of the days of illness are adjusted to match the time scale of a, b, and c. High IgG avidity indicate a distant infection of more than 5 months before. IgG avidity test of day 20 (cryopreserved serum) and day 239 were performed together on day 239

To rule out toxoplasmosis, which could also develop into lymphadenopathy, meningitis, and uveitis, Toxoplasma-specific IgG and IgM titers were evaluated on day 37 of illness, and revealed to be both positive 219 IU/mL (reference value < 6 U/mL) and 4.2 IE/mL (reference value < 0.8 U/mL) respectively. He had a dog for a pet, but not a cat. Despite the positivity of Toxoplasma IgM antibody, the bilateral uveitis responded well to the ophthalmic steroid therapy, lymphadenopathy disappeared,and no signs of meningitis was observed. We decided that antimicrobial therapy was not needed, and he was discharged on day 44 of illness. Drug-induced lymphocyte stimulation test (DLST) or lymphocyte transformation test (LTT), performed by a commercially based clinical diagnostic testing service (SRL, Inc., Tokyo, Japan), confirmed that the patient had a negative stimulation index (SI) score for levofloxacin, esomeprazole, ceftriaxone, and amoxicillin, while he had a high SI score exclusively for diclofenac sodium of 207% (reference value < 180%).

After discharge, uveitis recurrence was not detected, and ophthalmic steroid was terminated after 2 months of use. However, the titer of IgM of Toxoplasma remained at a high level for an additional 6 months; we were not sure whether Toxoplasma infection was implicated in this TINU syndrome (Fig. 2d). To address the question, Toxoplasma IgG avidity test was performed with serum sample of day 20 of illness stocked in freezer, and with fresh serum sample from day 239 of illness. The test was performed by a laboratory company (SRL) using Platelia (TM) TOXO IgG AVIDITY (Bio-Rad) according to the manufacturer’s protocol. In brief, optical density (OD) indicating Toxoplasma IgG in serum was measured by enzyme-linked immunosorbent assay (ELISA) after dissociating the link between antibody and antigen. Urea was used as the dissociating agent. Target antigen of the ELISA was purified from Toxoplasma gondii RH strain. Avidity Index (AI) was measured by the ratio of OD(dissociating agent treated) to OD(dissociating agent untreated). IgG AI of the above samples was 0.62 (day 20) and 0.66 (day 239) (reference value: low AI < 0.4, mid 0.4 ≤ AI < 0.5, high 0.5 ≤ AI), indicating a chronologically distant infection of more than 5 months before fever onset. Hence, we determined that the pathogenesis of TINU syndrome in our case was not implicated with a recent infection of Toxoplasma.

No recurrence of renal dysfunction was observed in the 18 months of follow-up; serum Cre levels were 1.21, 1.03, and 1.04 mg/dL on day 71, 92, and 239 of illness, respectively. Urinary beta-2-microglobulin was reduced to 234 μg/L (reference value < 229 μg/L) on day 204 of illness. HLA typing showed HLA-A3101, HLA-A3303, HLA-B4002, HLA-B4403, HLA-DR0802, HLA-DR1302. HLA-DQB1 0302, and HLA-DQB1 0604, none of which was reported to have strong association with TINU syndrome.


To diagnose TINU syndrome, differential diagnosis of infections and dozens of other systemic diseases are required. Among infections, Toxoplasma gondii is a pathogen with considerable prevalence on a global scale. Since IgM of Toxoplasma is known to persist in many cases [32], the chances of encountering patients with TINU syndrome with Toxoplasma IgM like our patient might not be so rare. Our case illustrates the difficulties in determining the pathogenic contribution of Toxoplasma gondii in a case of lymphadenopathy and meningitis followed by TINU syndrome. IgG avidity test seemed to rule out recent infection of Toxoplasma and led us to conclude that TINU syndrome in our case was not implicated with a recent infection of Toxoplasma. However, this process of interpretation may not be enough for a precise understanding of the infection profile of Toxoplasma in similar situations. The limitations of current commercial serological tests are also discussed here.

Diagnosis of TINU syndrome

A T-cell-mediated mechanism has been postulated for pathogenesis of TINU syndrome [1, 4, 35]. On analysis of kidney biopsy specimens from drug-induced tubulointerstitial nephritis (TIN), oligoclonal proliferation of drug-antigen-specific T cells was detected by staining of specific T-cell receptor beta-chain variable-region (TCR Vβ) [36]. The oligoclonal immune response is also reproduced in vitro with peripheral blood mononuclear cells from the same patients [36]. Also in TINU syndrome, under the same scenario, the proliferation of antigen-specific T cells initiates the adaptive immune response, which activates the humoral response with B cells. This process, delayed-type hypersensitivity reactions of type IV, causes immunopathologic damage to the uvea and renal interstitium [1]. Autoantibodies against modified CRP (mCRP) is proposed to be a marker for distinguishing TINU syndrome from drug-induced TIN [37, 38]. mCRP is presumed to be one of the common target autoantigens in renal and ocular tissues [37,38,39]. To demonstrate antigen-specific T cells, an in vitro assay called lymphocyte transformation test (LTT), or drug-induced lymphocyte stimulation test (DLST) is utilized as a useful diagnostic procedure for drug-induced TIN [40,41,42,43] and for TINU syndrome [44]. However, the sensitivity of this test for the detection of causative agents of drug hypersensitivity reactions is not adequate in some drugs (such as anti-tuberculosis drugs) [45]. Though the results of LTT/DLST may not be absolute [41, 42, 44, 46], we considered that our case was drug-induced TINU syndrome caused by diclofenac sodium. Diclofenac sodium was administered 5 days before the increment of serum Cre and 3 weeks before the development of uveitis, suggesting it is chronologically reasonable to infer that TIN and uveitis were both induced from diclofenac sodium. LTT/ DLST was performed as described by Pichler et al. [40]. In brief, 0.20 × 106 whole peripheral lymphocytes were stimulated with titrated density of medicine in culture medium (complete RPMI1640 medium), together with separately prepared serum from the same patient. Cultures were started in triplicate. After 72 hours, [3H] thymidine was added and cultured for an additional 24 hours, and the thymidine uptakes were counted from the harvested cells.

The major histologic changes of tubulointerstitial nephritis (TIN) are interstitial edema and intraepithelial infiltration of inflammatory cells in renal tubules, accompanied with destruction of tubular basement membranes (TBM), called tubulitis [47]. The infiltrated cells consist of T lymphocytes, monocytes, eosinophils, and plasma cells [43].

In a review of 40 renal biopsies of patients with granulomatous formation (37 of them are TIN), sarcoidosis was present in 50% of the patients, and drug-induced TIN was present in 18% [48]. In an area where infection is a more likely etiology, microbial pathogens such as Mycobacterium, tuberculosis, fungi, bacteria, spirochetes, and parasites (Leishmania, Toxoplasma) are associated with granulomatous TIN [48]. ANCA-associated vasculitis, Crohn’s disease, and TINU syndrome can also cause granulomatous formation in renal interstitium [43, 48]. Histological findings of tubulitis are classified into three groups by immunohistochemistry [47]: (1) negative for antibodies and immune deposits [49, 50]; (2) positive staining of immune complexes along the TBM that sometimes associates with complement [51]; and (3) linear staining of the TBM, usually with IgG and complement. The third group is known as anti-tubular basement membrane (anti-TBM) disease [52, 53].

Detailed diagnostic criteria for TINU syndrome were developed by John T. H. Mandeville and James T. Rosenbaum [4]. These criteria adopt a probabilistic approach to the diagnosis using the presented clinical features [1]. Based on the criteria, our patient is diagnosed as “definite” TINU syndrome (Table 1). As is noted in the criteria, the diagnosis of TINU syndrome requires the presence of both acute TIN and uveitis, without other systemic diseases that can cause TIN and uveitis. The important differential diagnosis suggested by the combination of fever, lymphadenopathy, anterior bilateral uveitis, and granulomatous interstitial nephritis is as follows; sarcoidosis, Sjogren’s syndrome, systemic lupus erythematosus, granulomatous with polyangiitis (GPA), Behcet’s syndrome, Epstein–Barr virus–associated infectious mononucleosis, tuberculosis, bacterial/fungal infections, toxoplasmosis, and histoplasmosis [4, 54].

Table 1 Diagnostic criteria for tubulointerstitial nephritis and uveitis syndrome

Distinction of sarcoidosis from TINU syndrome is particularly difficult [1]. In 736 patients of sarcoidosis, the percentage of renal involvement (renal sarcoidosis) was only 0.7% [55]. Another retrospective analysis of 47 patients with renal sarcoidosis reported that 90% of them had intrathoracic lesions, 66% had proteinuria, and 55% had increased ACE [56]. The lymph node enlargement in sarcoidosis is typically firm, nontender, and freely movable [57]. As opposed to this clinical phenotype, our case had lymphadenopathy with tenderness and did not have hilar lymphadenopathy, proteinuria, elevated ACE, and other findings such as hepatomegaly, nephrocalcinosis, or nephrolithiasis on CT scan and on Gallium scintigraphy. Moreover, uveitis, lymphadenopathy, and TIN activity in our case were appreciably alleviated without using systemic steroid in the 18 months of follow-up, which is contrasting to the high relapse rate of renal sarcoidosis even after strong steroid therapy [56]. This clinical presentation made drug-induced TINU syndrome more likely than renal sarcoidosis. Long-term follow-up would be needed to confirm this presumptive diagnosis.

The first TINU syndrome cases were described as “Acute eosinophilic interstitial nephritis with uveitis” by Dobrin [2]. From this description, one can infer that eosinophils may play a certain role in the pathogenesis of TINU syndrome. Eosinophilia is included in the diagnostic criteria of TINU syndrome as one of the manifestations of acute interstitial nephritis [4]. Systemic eosinophilia is reported in 17% of TINU syndrome patients (21 of 122 cases) [4]. Mild elevations of eosinophils were observed also in our case. Interestingly, the level of peripheral eosinophils showed two peaks in the clinical course. These peaks were noticed when reviewing the data retrospectively. The first peak was recorded in parallel with the upregulation of serum Cre, or the development of TIN. The second peak was recorded around 4–5 days before the development of uveitis. These fluctuations of eosinophils might reflect the pathogenesis of TINU syndrome. Whether peripheral eosinophils can be used as a prognostic or activation marker of TINU syndrome symptoms should be investigated.

TINU syndrome is probably an underdiagnosed disorder [4]. TINU syndrome would not have been diagnosed if the association of interstitial nephritis and uveitis were not clinically evident, or if one of the symptoms had resolved by the time other symptoms developed. TINU syndrome cases are diagnosed in 0.2–2% of patients attending specialist uveitis services [58], and in 0.4% (n = 15/3830) of uveitis patients in Japan [59]. Drugs and infections have been proposed as the leading acquired risk factors for the development of TINU syndrome. Larger datasets from renal literatures also suggest that most cases of TINU syndrome are caused by drug-induced hypersensitivity reaction [58]. Contrary to the differential diagnosis described in the above paragraph, specific infective agents reported as being possibly associated with TINU syndrome include tuberculosis [60], EBV [61,62,63], herpes zoster reactivation [63], systemic toxoplasmosis [8], and generalized lymphadenopathy [8].

A review summarizing 133 TINU syndrome cases noted that the main drugs proposed as risk factors for TINU syndrome are nonsteroidal antiinflammatory agents (18%) and antibiotics (24%) [4]. There is a case of levofloxacin-related anterior uveitis, vitritis, and macular edema that required oral prednisone to return to baseline vision in an adult female [64]. The most common causative drug for uveitis is bisphosphonate, which is employed in the treatment of osteoporosis or of dystrophic disease involving the skeletal system. Bisphosphonates have been associated with uveitis, nonspecific conjunctivitis, episcleritis, and scleritis. Several antibiotics have been causally linked to uveitis, most notably rifabutin, sulfonamides, and fluoroquinolones. Sulfonamide-associated uveitis develops quickly, often as fast as 8 days [64]. Esomeprazole, a proton pump inhibitor (PPI), was resumed 2 months after discontinuation, without any complications thereafter. This indicates that esomeprazole had little effect on the pathogenesis of our TINU syndrome, although PPIs are common causative drugs for drug-induced TIN, like antibiotics and NSAIDs [65, 66]. Increased pH in stomach helps the survival of tachyzoites of Toxoplasma gondii [67]. In the view of susceptibility to ingested infectious agents, the high pH may make it difficult to completely deny the contribution of esomeprazole to pathogenesis.

TIN and uveitis symptoms are not always concurrent. The review summarizing 133 TINU syndrome cases noted that ocular symptoms were concurrent with systemic symptoms in only 15% of cases; in 21% of cases, uveitis occurred before systemic symptoms, occurring up to 2 months beforehand; in 65% of cases, uveitis occurred after systemic symptoms with a median of 3 months, up to 14 months [4, 58]. Based on the study, eye pain and redness were observed in 41% (n = 55/133), blurred vision in 10.5% (n = 14/133), anterior uveitis in 73% (n = 97/133), and keratic precipitation in 9.8% (n = 13/133) of the TINU syndrome cases [4]. Another review summarizing 2619 uveitis cases reported that viral infections were seen in 8.6% (n = 226/2619) and parasitic infections in 7.5% of cases (n = 198/2619), most of which were Toxoplasma infection (n = 173) [68]. Most viral infection-related uveitis anatomically localized in the anterior (81%, n = 183/226), whereas most parasitic infection-related uveitis localized in the posterior part (77%, n = 153/198). This suggests that the bilateral anterior uveitis observed in our case was more likely to be TINU syndrome or viral infection related rather than parasitic infection related.

Urinary beta-2-microglobulin is widely used as an interstitial damage marker. In our case, it was highly elevated in the acute phase and gradually reduced to a normal level in parallel with remission of the illness. Consistent with our case, a review reported that urinary beta-2-microglobulin levels were elevated in all cases of tested TINU syndrome (100%, n = 37/37) and persisted for months [4]. Persistent histological change was reported in the two tested cases even at second biopsy 9 months after the first diagnosis of TINU syndrome [69]. They suggest a requirement of immunosuppressive therapy in selected TINU syndrome patients [69]. Urine TNFα and IL-9 levels are proposed to be good biomarkers to improve the prebiopsy diagnosis for acute interstitial nephritis [70], because TINU syndrome is thought to be a lymphocyte-mediated immune response [1].

Interpretation of Toxoplasma serology

The second most common cause of encephalitis deaths in the USA is Toxoplasma gondii, following herpesvirus [6]. A common cause of uveitis in immunocompetent hosts is Toxoplasma gondii. As many as 2% of Toxoplasma-infected patients exhibit ocular toxoplasmosis, which can be present either in the context of recently acquired infection (recent infection) or of reactivated disease as retinochoroiditis [71]. Retinochoroiditis scarring has been considered as a finding of congenital infection, but is increasingly recognized as a result of acquired recent infection [72]. Therefore, clinicians have a good chance of seeing an immunocompetent patient with subacute Toxoplasma infections. However, medical literature related to acquired toxoplasmosis in immunocompetent patients is not enough [16], probably because acquired toxoplasmosis has been considered to be basically self-limiting.

IgG avidity test of Toxoplasma was originally developed by Hedman and his associates in Finland [73]. Maturation of antibody affinity to target antigen occurs in the weeks or months after the primary infection. IgG avidity is initially low in the first 3 months (may remain to be low for 1 year), and achieves a higher level in the late phase of (distant) infection (4–5 months) [34]. IgG avidity is necessary as confirmatory testing to distinguish the recent infection of Toxoplasma from patients with persistent IgM or false positive IgM [32]. In our case, although positivity of IgG and IgM of Toxoplasma was obtained, we only periodically monitored the level of IgG and IgM. Despite the lack of headache, fever, and uveitis, the persisting IgM confused our interpretation of the serological results, and urged us to perform IgG avidity of Toxoplasma. The test is still in the research phase and not covered by health insurance in Japan. The IgG avidity test performed on the frozen sample of day 20 of illness indicated a distant infection. Therefore, complication of a recent infection of Toxoplasma on his pathogenesis was excluded accordingly.

A limitation of our investigation is that commercial Toxoplasma IgM and IgG tests cannot distinguish different strains of Toxoplasma gondii. Although reinfection of Toxoplasma gondii does not basically occur in immune-competent hosts except in some rare case reports [74,75,76,77,78], this may be true exclusively for the same strain. There are several strains in Toxoplasma gondii with different virulence, and prevalence varies depending on geographical factors [79, 80]. Contrary to the accepted notion above, a reinfection experiment in sheep model demonstrated that reinfection of a different strain of Toxoplasma gondii on preimmune sheep with the preceding infection does occur [81]. There is a case report of human reinfection by a different strain of Toxoplasma that was not protected by the immunity of the preceding strain of Toxoplasma [82] (Fig. 3a, lower right). The authors and others [83,84,85,86] also confirmed that acquired immunity against a preceding strain of Toxoplasma may not protect against reinfection by another strain, based on mouse model experiments. Although there is no evidence of increased risk of Toxoplasma infection for plumbers who are frequently exposed to sewage water [87], oocysts are persistent and prevalent in water, soil, and foods [88]. Also, vegetarians and certain occupations such as farmers are significantly more associated with Toxoplasma IgM seropositivity [89].

Fig. 3

Toxoplasma serology tests in primary infection, reactivation, and in reinfection. a The transmission of Toxoplasma gondii to immunocompetent humans (intermediate host) occurs by ingestion of oocysts, normally via contaminated food or water. Infection can also occur via consumption of undercooked meat or raw meat containing tissue cysts with bradyzoites. The majority of cases (85–90%) are asymptomatic, but around 10–15% of the infected individuals develop systemic symptoms [12,13,14,15]. In either case, chronic (distant) infection can persist for the life of the hosts. If the hosts become immunodeficient or immune-suppressed, bradyzoites reactivate, which causes cerebral or ocular toxoplasmosis. If primary infection occurs during pregnancy, parasites can also infect the fetus by congenital transmission. Typical Toxoplasma serological changes of primary infection in immunocompetent patients are shown in b. The first isotype antibody to appear in the very early phase of the primary infection is IgM, followed by the appearance of IgG, which is required for confirmation of the infection. Toxoplasma IgG avidity test is a critical tool to distinguish recent infection from distant infection in pregnant women, because IgM of Toxoplasma is known to persist in many cases of distant infection [29,30,31,32] (persistent IgM is marked with * in this figure). However, congenital transmission also occurs in distant/latent infected host when the host becomes immunodeficient (a, lower left) or reinfected with different strains of Toxoplasma gondii (a: lower right). In such cases, commercial IgG avidities give high-level results even before the onset of reactivation or reinfection, because the hosts have been distantly/latently infected. Therefore, clinicians cannot interpret IgG avidity test as they do in primary infection. Clinically symptomatic phases are highlighted in yellow. Blue dot line indicates the “distant infection” profile, which consists of three infection profiles: latent infection, reactivation, and reinfection. Different strains of Toxoplasma gondii are described as oocysts-2 or tissue cysts-2. Representative changes of Toxoplasma gondii serology in reactivation and in reinfection are shown in c and d. In d, distinctive serological changes of reinfection from serum of reactivation are written in red letter. IgG, IgM, IgA, Toxoplasma gondii-specific IgG, IgM, IgA; Inf, infection; Pos, positive; Neg, negative; Pos/higher, positive or higher level; v.e, very early phase of infection. Recent infection is highlighted in pink, and distant infection is highlighted in light blue. This figure is modified from Vera Lucia Pereira-Chioccola et al. [15] and O Villard et al. [93]. Ref A-K, reference group A–K; Ref. A: [90, 91], Ref. B: [96], Ref. C: [74,75,76,77, 78(p), 82(p), 94, 96]; p, presumed cases; Ref. D: [91], Ref. E: [91], Ref. F: [93], Ref. G: [74, 77, 82, 94], Ref. H: [74, 76, 77], Ref. I: [74, 91, 96], Ref. J: [74, 76, 77], Ref. K: [17, 93], Ref. L: [17]

Besides reinfection, recurrence or reactivation of the primary infection is another type of “distant” Toxoplasma infection profile. Reactivation mostly occurs in immunosuppressed conditions [15]. Reactivation causes cerebral, ocular, or congenital toxoplasmosis [90, 91] (Fig. 3a, lower left). A retrospective serological analysis found that, among 217 cases of serologically positive ocular toxoplasmosis, only 3.2% were in recent primary infection profile, while 68.2% were in a distant (chronic) infection profile based on IgG avidity test [92]. Direct detection of Toxoplasma gondii is basically required for the confirmation of reactivated toxoplasmosis. For the detection, bioassay of suspected biological materials in laboratory mice or PCR tests targeting gene sequences of Toxoplasma are utilized [5]. Thus, the initial serological results of our case (positive IgG and IgM) indicate any of the following profiles: (1) recent primary infection; (2) latent/distant infection of primary infection (with persistent IgM); (3) recent infection of a different strain (reinfection); or (4) recurrence/reactivation of latent infection. The following serological results and the high IgG avidity in our case excluded the possibility of (1) recent primary infection. However, high titer and high avidity IgG generated by distant/preceding infections might mask the detection of low avidity IgG generated by a recent infection with a different strain. Therefore, the “distant” infection indicated by commercial IgG avidity test is still a multiplex profile consisting of (3) reinfection, (4) reactivation, and (2) latent infection [93]. Ranges of distant infection are described as light blue rectangle at left side in Fig. 3a.

The positivity of serum Toxoplasma IgA is reported to be a proof of reinfection and not of reactivation [74, 77, 82, 94]. In primary infection, Toxoplasma IgA appears shortly after IgM and persists for some time (usually 6–7 months) [95]. Reappearance of Toxoplasma IgM in previously infected patients is another serological marker of reinfection and not of reactivation [74, 91, 96], although this rule is applicable only in the absence of persistent IgM. However, reappearance of IgM is not always detected in reinfection-presumed cases [75,76,77]. Increased IgG of Toxoplasma observed at reinfection [74, 76, 77] or at reactivation [93] should be interpreted carefully, because such a rise is also observed in a delayed serological response to antigens after treatment of toxoplasmosis [97]. Serological variations in each infection profile are summarized in tables in Fig. 3b–d.

Evaluation of Toxoplasma IgA was not performed in our case. PCR detection from suspected biological materials was not attempted. The fact that the patient was not immunodeficient or immune-suppressed suggested that (4) reactivation was not likely. No remarkable change in Toxoplasma IgG throughout the clinical course suggested that (2) latent/distant infection was more likely than (3) reinfection or (4) reactivation. On the other hand, our case fortunately satisfied the diagnostic criteria for TINU syndrome. Based on the whole clinical course, we were able to interpret the serological results of Toxoplasma as (2) latent infection rather than (3) reinfection. It should be noted that making this diagnosis in the middle of the course was difficult. Protein microarray survey has identified a number of target antigens for IgG and IgM, from serum of Toxoplasma-infected patients [98]. Several efforts to identify strain-specific antigens [80, 83, 99,100,101] or stage-specific antigens [102,103,104] that enable more specific serotyping of Toxoplasma gondii have been reported. Future development of serological examination of Toxoplasma should facilitate the clinical diagnosis of autoimmune diseases such as TINU syndrome.


This case illustrates the difficulty in determining the infection profile of Toxoplasma gondii in the diagnosis of TINU syndrome. Performing the IgG avidity test in a timely manner is recommended to determine the chronological assessment of the putative Toxoplasma gondii infection. However, these serological examinations still have limitations in their precise determination of the infection profile. Therefore, careful monitoring and extended follow-up of such patients are critical.

Availability of data and materials

Data sharing is not applicable to this article because no datasets were generated or analyzed during the current study.


TINU syndrome:

Tubulointerstitial nephritis and uveitis syndrome


Drug-induced lymphocyte stimulation test


Lymphocyte transformation test


Tubular basement membranes


Best-corrected visual acuity


Keratic precipitation


Nonsteroidal antiinflammatory agent/drug


C-reactive protein




Computed tomography


Cerebrospinal fluid


White blood cell




Glomerular filtration rate


Fractional excretion of sodium


Angiotensin-converting enzyme


Anti-neutrophil cytoplasmic antibody


Anti-nuclear antibody


Glomerular basement membrane


Epstein–Barr virus




Stimulation index


Human leukocyte antigen


  1. 1.

    Clive DM, Vanguri VK. The syndrome of tubulointerstitial nephritis with uveitis (TINU). Am J Kidney Dis. 2018;72(1):118–28. (Epub 2018 Feb 9, 2018).

    Article  PubMed  Google Scholar 

  2. 2.

    Dobrin RS, Vernier RL, Fish AL. Acute eosinophilic interstitial nephritis and renal failure with bone marrow-lymph node granulomas and anterior uveitis. A new syndrome. Am J Med. 1975;59(3):325–33.

    CAS  Article  Google Scholar 

  3. 3.

    Matsumoto K, Fukunari K, Ikeda Y, Miyazono M, Kishi T, Matsumoto R, Fukuda M, Uchiumi S, Yoshizaki M, Nonaka Y, Kanaya A. A report of an adult case of tubulointerstitial nephritis and uveitis (TINU) syndrome, with a review of 102 Japanese cases. Am J Case Rep. 2015;16:119–23.

    Article  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Mandeville JT, Levinson RD, Holland GN. The tubulointerstitial nephritis and uveitis syndrome. Surv Ophthalmol. 2001;46(3):195–208.

    CAS  Article  Google Scholar 

  5. 5.

    Sepulveda-Arias JC, Gomez-Marin JE, Bobic B, Naranjo-Galvis CA, Djurkovic-Djakovic O. Toxoplasmosis as a travel risk. Travel Med Infect Dis. 2014;12(6 Pt A):592–601. (Epub 2014 Jun 7, 2017).

    Article  PubMed  Google Scholar 

  6. 6.

    Tack DM, Holman RC, Folkema AM, Mehal JM, Blanton JD, Sejvar JJ. Trends in encephalitis-associated deaths in the United States. Neuroepidemiology. 2014;43(1):1–8. (Epub 2014 Jun 24, 2008).

    Article  PubMed  Google Scholar 

  7. 7.

    Dunay IR, Gajurel K, Dhakal R, Liesenfeld O, Montoya JG. Treatment of toxoplasmosis: historical perspective, animal models, and current clinical practice. Clin Microbiol Rev. 2018;31(4):e00057-e117. (Print 2018 Oct 2018).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  8. 8.

    Guignard JP, Torrado A. Interstitial nephritis and toxoplasmosis in a 10-year-old child. J Pediatr. 1974;85(3):381–2.

    CAS  Article  Google Scholar 

  9. 9.

    Wickbom B, Winberg J. Coincidence of congenital toxoplasmosis and acute nephritis with nephrotic syndrome. Acta Paediatr Scand. 1972;61(4):470–2.,1972.

    CAS  Article  PubMed  Google Scholar 

  10. 10.

    Figueiredo AC, Rodrigues L, Sousa V, Alves R. Granulomatous interstitial nephritis: a rare diagnosis with an overlooked culprit. BMJ Case Rep. 2019;12(8):e229159.

    Article  PubMed  PubMed Central  Google Scholar 

  11. 11.

    Ulinski T, Sellier-leclerc A, Tudorache E, Bensman A, Aoun B. Acute tubulointerstitial nephritis. Pediatr Nephrol. 2012;27(7):1051–7. (Epub 2011 Jun 3, 2017).

    Article  PubMed  Google Scholar 

  12. 12.

    Basit KA, Nasir S, Vohra E, Shazlee MK. Toxoplasmosis in an immunocompetent patient. Pak J Med Sci. 2018;34(6):1579–81.

    PubMed  PubMed Central  Google Scholar 

  13. 13.

    Kaparos N, Favrat B, D’Acremont V. Fever and lymphadenopathy: acute toxoplasmosis in an immunocompetent patient (article in French). Rev Med Suisse. 2014;10(452):2264.

    PubMed  Google Scholar 

  14. 14.

    Taila AK, Hingwe AS, Johnson LE. Toxoplasmosis in a patient who was immunocompetent: a case report. J Med Case Rep. 2011;5:16.

    Article  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Pereira-Chioccola VL, Ernesto VJ, Su C. Toxoplasma gondii infection and cerebral toxoplasmosis in HIV-infected patients. Future Microbiol. 2009;4(10):1363–79.

    Article  PubMed  Google Scholar 

  16. 16.

    Neves ES, Bicudo LN, Curi AL, Carregal E, Bueno WF, Ferreira RG, Amendoeira MR, Benchimol E, Fernandes O. Acute acquired toxoplasmosis: clinical-laboratorial aspects and ophthalmologic evaluation in a cohort of immunocompetent patients. Mem Inst Oswaldo Cruz. 2009;104(2):393–6.

    CAS  Article  PubMed  Google Scholar 

  17. 17.

    Jenum PA, Stray-Pedersen B. Development of specific immunoglobulins G, M, and A following primary Toxoplasma gondii infection in pregnant women. J Clin Microbiol. 1998;36(10):2907–13.

    CAS  Article  Google Scholar 

  18. 18.

    O’Connell S, Guy EC, Dawson SJ, Francis JM, Joynson DH. Chronic active toxoplasmosis in an immunocompetent patient. J Infect. 1993;27(3):305–10.

    CAS  Article  PubMed  Google Scholar 

  19. 19.

    Demar M, Hommel D, Djossou F, Peneau C, Boukhari R, Louvel D, Bourbigot A-M, Nasser V, Ajzenberg D, Darde M-L, Carme B. Acute toxoplasmoses in immunocompetent patients hospitalized in an intensive care unit in French Guiana. Clin Microbiol Infect. 2012;18(7):E221–31. (Epub 2011 Sep 29, 2012).

    CAS  Article  PubMed  Google Scholar 

  20. 20.

    Sakikawa M, Noda S, Hanaoka M, Nakayama H, Hojo S, Kakinoki S, Nakata M, Yasuda T, Ikenoue T, Kojima T. Anti-Toxoplasma antibody prevalence, primary infection rate, and risk factors in a study of toxoplasmosis in 4,466 pregnant women in Japan. Clin Vaccine Immunol. 2012;19(3):365–7.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  21. 21.

    Bigna JJ, Tochie JN, Tounouga DN, Bekolo AO, Ymele NS, Youda EL, Sime PS, Nansseu JR. Global, regional, and country seroprevalence of Toxoplasma gondii in pregnant women: a systematic review, modelling and meta-analysis. Sci Rep. 2020;10(1):12102.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  22. 22.

    Nayeri T, Sarvi S, Moosazadeh M, Amouei A, Hosseininejad Z, Daryani A. The global seroprevalence of anti-Toxoplasma gondii antibodies in women who had spontaneous abortion: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2020;14(3):e0008103. (eCollection2020 Mar).

    Article  PubMed  PubMed Central  Google Scholar 

  23. 23.

    Brooks RG, McCabe RE, Remington JS. Role of serology in the diagnosis of toxoplasmic lymphadenopathy. Rev Infect Dis. 1987;9(5):1055–62.,1987.

    CAS  Article  PubMed  Google Scholar 

  24. 24.

    Herbrink P, van Loon AM, Rotmans JP, van Knapen F, van Dijk WC. Interlaboratory evaluation of indirect enzyme-linked immunosorbent assay, antibody capture enzyme-linked immunosorbent assay, and immunoblotting for detection of immunoglobulin M antibodies to Toxoplasma gondii. J Clin Microbiol. 1987;25(1):100–5.

    CAS  Article  Google Scholar 

  25. 25.

    Naot Y, Remington JS. An enzyme-linked immunosorbent assay for detection of igm antibodies to Toxoplasma gondii: use for diagnosis of acute acquired toxoplasmosis. J Infect Dis. 1980;142(5):757–66.,1980.

    CAS  Article  PubMed  Google Scholar 

  26. 26.

    Wielaard F, van Gruijthuijsen H, Duermeyer W, Joss AW, Skinner L, Williams H, van Elven EH. Diagnosis of acute toxoplasmosis by an enzyme immunoassay for specific immunoglobulin M antibodies. J Clin Microbiol. 1983;17(6):981–7.

    CAS  Article  Google Scholar 

  27. 27.

    Bono DV, Canessa A, Bruzzi P, Fiorelli MA, Terragna A. Significance of specific immunoglobulin M in the chronological diagnosis of 38 cases of toxoplasmic lymphadenopathy. J Clin Microbiol. 1989;27(9):2133–5.

    Article  Google Scholar 

  28. 28.

    Gras L, Gilbert RE, Wallon M, Peyron F, Cortina-Borja M. Duration of the IgM response in women acquiring Toxoplasma gondii during pregnancy: implications for clinical practice and cross-sectional incidence studies. Epidemiol Infect. 2004;132(3):541–8.

    CAS  Article  Google Scholar 

  29. 29.

    Leite M, Siciliano S, Rocha LSA, Justa MTR, César KR, Granato CFH. Correlation between specific IgM levels and percentage IgG-class antibody avidity to Toxoplasma gondii. Rev Inst Med Trop Sao Paulo. 2008;50(4):237–42.

    Article  PubMed  Google Scholar 

  30. 30.

    Alver O, Payaslioglu M, Ener B. Investigation of Toxoplasma gondii seropositivity in Uluda? University Hospital between 2009–2016. Turkiye Parazitol Derg. 2019;43(Suppl 1):8–12.

    Article  PubMed  Google Scholar 

  31. 31.

    Yamada H, Tanimura K, Deguchi M, Tairaku S, Morizane M, Uchida A, Ebina Y, Nishikawa A. A cohort study of maternal screening for congenital Toxoplasma gondii infection: 12 years’ experience. J Infect Chemother. 2019;25(6):427–30. (Epub 2019 Feb 26).

    Article  PubMed  Google Scholar 

  32. 32.

    Yamada H, Nishikawa A, Yamamoto T, Mizue Y, Yamada T, Morizane M, Tairaku S, Nishihira J. Prospective study of congenital toxoplasmosis screening with use of IgG avidity and multiplex nested PCR methods. J Clin Microbiol. 2011;49(7):2552–6. (Epub 2011 May 4).

    Article  PubMed  PubMed Central  Google Scholar 

  33. 33.

    Pelloux H, Brun E, Vernet G, Marcillat S, Jolivet M, Guergour D, Fricker-Hidalgo H, Goullier-Fleuret A, Ambroise-Thomas P. Determination of anti-Toxoplasma gondii immunoglobulin G avidity: adaptation to the Vidas system (bioMérieux). Diagn Microbiol Infect Dis. 1998;32(2):69–73.

    CAS  Article  Google Scholar 

  34. 34.

    Remington JS, Thulliez P, Jose G. Montoya: recent developments for diagnosis of toxoplasmosis. J Clin Microbiol. 2004;42(3):941–5.

    Article  Google Scholar 

  35. 35.

    Yoshioka K, Takemura T, Kanasaki M, Akano N, Maki S. Acute interstitial nephritis and uveitis syndrome: activated immune cell infiltration in the kidney. Pediatr Nephrol. 1991;5(2):232–4.

    CAS  Article  PubMed  Google Scholar 

  36. 36.

    Spanou Z, Keller M, Britschgi M, Yawalkar N, Fehr T, Neuweiler J, Gugger M, Mohaupt M, Pichler WJ. Involvement of drug-specific T cells in acute drug-induced interstitial nephritis. J Am Soc Nephrol. 2006;17(10):2919–27. (Epub 2006 Aug 30).

    CAS  Article  PubMed  Google Scholar 

  37. 37.

    Li C, Su T, Chu R, Li X, Yang L. Tubulointerstitial nephritis with uveitis in Chinese adults. Clin J Am Soc Nephrol. 2014;9(1):21–8. (Epub 2013 Nov 7).

    CAS  Article  PubMed  Google Scholar 

  38. 38.

    Tan Y, Yu F, Qu Z, Su T, Xing GQ, Wu LH, Wang FM, Liu G, Yang L, Zhao MH. Modified C-reactive protein might be a target autoantigen of TINU syndrome. Clin J Am Soc Nephrol. 2011;6(1):93–100. (Epub 2010 Sep 2).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  39. 39.

    Santoro D, Vita G, Rovito S, Venuto L, Cavallari V, Vita R, Savica V, Bellinghieri G, Gangemi S. Drug-induced TINU syndrome and genetic characterization. Clin Nephrol. 2012;78(3):230–6.

    CAS  Article  PubMed  Google Scholar 

  40. 40.

    Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy. 2004;59(8):809–20.

    CAS  Article  PubMed  Google Scholar 

  41. 41.

    Onishi A, Yamamoto H, Akimoto T, Saito O, Inoue M, Ando Y, Muto S, Kusano E. Reversible acute renal failure associated with clomipramine-induced interstitial nephritis. Clin Exp Nephrol. 2007;11(3):241–3. (Epub 2007 Sep 28).

    Article  PubMed  Google Scholar 

  42. 42.

    Akimoto T, Horikoshi R, Muto S, Kusano E. Low-dose corticosteroid and gallium-67 scintigraphy and acute interstitial nephritis. Saudi J Kidney Dis Transpl. 2014;25(4):864–8.

    Article  PubMed  Google Scholar 

  43. 43.

    Baker RJ, Pusey CD. The changing profile of acute tubulointerstitial nephritis. Nephrol Dial Transplant. 2004;19(1):8–11.

    Article  PubMed  Google Scholar 

  44. 44.

    Suzuki H, Yoshioka K, Miyano M, Maeda I, Yamagami K, Morikawa T, Okada N, Konishi Y, Imanishi M. Tubulointerstitial nephritis and uveitis (TINU) syndrome caused by the Chinese herb “Goreisan.” Clin Exp Nephrol. 2009;13(1):73–6. (Epub 2008 Jul 26).

    Article  PubMed  Google Scholar 

  45. 45.

    Suzuki Y, Miwa S, Shirai M, Ohba H, Murakami M, Fujita K, Suda T, Nakamura H, Hayakawa H, Chida K. Drug lymphocyte stimulation test in the diagnosis of adverse reactions to antituberculosis drugs. Chest. 2008;134(5):1027–32. (Epub 2008 Jun 26).

    CAS  Article  PubMed  Google Scholar 

  46. 46.

    Manabu N, Ohji G, Kentaro I. Acute tubulointerstitial nephritis caused by rifampicin: an increasing and often overlooked side effect in elderly patients. Int J Clin Pharmacol Ther. 2019;57(5):264–9.

    Article  Google Scholar 

  47. 47.

    Neilson EG. Pathogenesis and therapy of interstitial nephritis. Kidney Int. 1989;35(5):1257–70.

    CAS  Article  PubMed  Google Scholar 

  48. 48.

    Javaud N, Belenfant X, Stirnemann J, Laederich J, Ziol M, Callard P, Ronco P, Rondeau E, Fain O. Renal granulomatoses: a retrospective study of 40 cases and review of the literature. Medicine (Baltimore). 2007;86(3):170–80.,2007.

    Article  Google Scholar 

  49. 49.

    McCluskey RT, Colvin RB. Immunologic aspects of renal tubular and interstitial diseases. Annu Rev Med. 1978;29:191–203.

    CAS  Article  PubMed  Google Scholar 

  50. 50.

    Andres GA, McCluskey RT. Tubular and interstitial renal disease due to immunologic mechanisms. Kidney Int. 1975;7(4):271–89.

    CAS  Article  PubMed  Google Scholar 

  51. 51.

    Klassen J, Andres GA, Brennan JC, McCluskey RT. An immunologic renal tubular lesion in man. Clin Immunol Immunopathol. 1972;1(69–83):1972.

    Google Scholar 

  52. 52.

    Klassen J, Kano K, Milgrom F, Menno AB, Anthone S, Anthone R, Sepulveda M, Elwood CM, Andres GA. Tubular lesions produced by autoantibodies to tubular basement membrane in human renal allografts. Int Arch Allergy Appl Immunol. 1973;45(5):675–89.,1973.

    CAS  Article  PubMed  Google Scholar 

  53. 53.

    Bergstein J, Litman N. Interstitial nephritis with anti-tubular-basement-membrane antibody. N Engl J Med. 1975;292(17):875–8.

    CAS  Article  PubMed  Google Scholar 

  54. 54.

    Joyce E, Glasner P, Ranganathan S, Swiatecka-Urban A. Tubulointerstitial nephritis: diagnosis, treatment, and monitoring. Pediatr Nephrol. 2017;32(4):577–87.

    Article  PubMed  Google Scholar 

  55. 55.

    Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H Jr, Bresnitz EA, DePalo L, Hunninghake G, Iannuzzi MC, Johns CJ, McLennan G, Moller DR, Newman LS, Rabin DL, Rose C, Rybicki B, Weinberger SE, Terrin ML, Knatterud GL, Cherniak R. Case Control Etiologic Study of Sarcoidosis (ACCESS) research group: clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164(10 Pt 1):1885–9.

    CAS  Article  PubMed  Google Scholar 

  56. 56.

    Mahévas M, Lescure FX, Jean-Jacques B, Delastour V, Belenfant X, Chapelon C, Cordonnier C, Makdassi R, Jean-Charles P, Jean-Marc N, Cadranel J, Duhaut P, Choukroun G, Ducroix JP, Valeyre D. Renal sarcoidosis: clinical, laboratory, and histologic presentation and outcome in 47 patients. Medicine. 2009;88:98.

    Article  Google Scholar 

  57. 57.

    Shetty AK, Gedalia A. Sarcoidosis: a pediatric perspective. Clin Pediatr (Phila). 1998;37(12):707–17.

    CAS  Article  Google Scholar 

  58. 58.

    Okafor LO, Hewins P, Murray PI, Denniston AK. Tubulointerstitial nephritis and uveitis (TINU) syndrome: a systematic review of its epidemiology, demographics and risk factors. Orphanet J Rare Dis. 2017;12(1):128.

    Article  PubMed  PubMed Central  Google Scholar 

  59. 59.

    Moorthy RS, Valluri S, Jampol LM. Drug-induced uveitis. Surv Ophthalmol. 1998;42(6):557–70.

    CAS  Article  PubMed  Google Scholar 

  60. 60.

    Dursun I, Yikilmaz A, Poyrazoglu H, Soyuer I, Gunduz Z. Radiological findings of isolated hepatic tuberculosis in a child with tubulointerstitial nephritis-uveitis syndrome. Pediatr Radiol. 2009;39(3):302–5.

    Article  PubMed  Google Scholar 

  61. 61.

    Grefer J, Santer R, Ankermann T, Faul S, Nölle B, Eggert P. Tubulointerstitial nephritis and uveitis in association with Epstein-Barr virus infection. Pediatr Nephrol. 1999;13(4):336–9.

    CAS  Article  PubMed  Google Scholar 

  62. 62.

    Ashorn P, Helin H, Baer M, Mustonen J. Tubulo-interstitial nephritis and uveitis in a 13-year old boy (Article in Finnish). Duodecim. 1992;108(23–24):2125–9.

    CAS  PubMed  Google Scholar 

  63. 63.

    Ljutic D, Glavina M. Tubulointerstitial nephritis with uveitis syndrome following varicella zoster reactivation. Nephron. 1995;71(4):485–6.

    CAS  Article  PubMed  Google Scholar 

  64. 64.

    London NJ, Garg SJ, Moorthy RS, Cunningham ET. Drug-induced uveitis. J Ophthalmic Inflamm Infect. 2013;3(1):43.

    Article  PubMed  PubMed Central  Google Scholar 

  65. 65.

    Muriithi AK, Leung N, Valeri AM, Cornell LD, Sethi S, Fidler ME, Nasr SH. Clinical characteristics, causes and outcomes of acute interstitial nephritis in the elderly. Kidney Int. 2015;87(2):458–64. (Epub 2014 Sep 3).

    CAS  Article  PubMed  Google Scholar 

  66. 66.

    Wilson GJ, Kark AL, Francis LP, Hoy W, Healy HG, Mallett AJ. The increasing rates of acute interstitial nephritis in Australia: a single centre case series. BMC Nephrol. 2017;18(1):329.

    Article  PubMed  PubMed Central  Google Scholar 

  67. 67.

    Koethe M, Schade C, Fehlhaber K, Ludewig M. Survival of Toxoplasma gondii tachyzoites in simulated gastric fluid and cow’s milk. Vet Parasitol. 2017;233:111–4. (Epub 2016 Dec 14).

    CAS  Article  PubMed  Google Scholar 

  68. 68.

    Barisani-Asenbauer T, Maca SM, Mejdoubi L, Emminger W, Machold K, Auer H. Uveitis—a rare disease often associated with systemic diseases and infections—a systematic review of 2619 patients. Orphanet J Rare Dis. 2012;7:57.

    Article  PubMed  PubMed Central  Google Scholar 

  69. 69.

    Yanagihara T, Kitamura H, Aki K, Kuroda N, Fukunaga Y. Serial renal biopsies in three girls with tubulointerstitial nephritis and uveitis syndrome. Pediatric Nephrol. 2009.

    Article  Google Scholar 

  70. 70.

    Moledina DG, Wilson FP, Pober JS, Perazella MA, Singh N, Luciano RL, Obeid W, Lin H, Kuperman M, Moeckel GW, Kashgarian M, Cantley LG, Parikh CR. Urine TNF-α and IL-9 for clinical diagnosis of acute interstitial nephritis. JCI Insight. 2019;4(10):127456. (eCollection 2019 May 16).

    Article  PubMed  Google Scholar 

  71. 71.

    Holland GN. Ocular toxoplasmosis: a global reassessment. Part I: epidemiology and course of disease. Am J Ophthalmol. 2003;136(6):973–88.

    Article  PubMed  Google Scholar 

  72. 72.

    Bosch-Driessen LE, Berendschot TT, Ongkosuwito JV, Rothova A. Ocular toxoplasmosis: clinical features and prognosis of 154 patients. Ophthalmology. 2002;109(5):869.

    Article  Google Scholar 

  73. 73.

    Hedman K, Lappalainen M, Seppäiä I, Mäkelä O. Recent primary toxoplasma infection indicated by a low avidity of specific IgG. J Infect Dis. 1989;159(4):736–40.

    CAS  Article  PubMed  Google Scholar 

  74. 74.

    Gavinet MF, Robert F, Firtion G, Delouvrier E, Hennequin C, Maurin JR, Tourte-Schaefer C, Dupouy-Camet J. Congenital toxoplasmosis due to maternal reinfection during pregnancy. J Clin Microbiol. 1997;35(5):1276–7.

    CAS  Article  Google Scholar 

  75. 75.

    Fortier B, Aïssi E, Ajana F, Dieusart P, Denis P, Martin E, de Lassalle M, Lecomte-Houcke DV. Spontaneous abortion and reinfection by Toxoplasma gondii. Lancet. 1991;338(8764):444.

    CAS  Article  PubMed  Google Scholar 

  76. 76.

    Hennequin C, Dureau P, N’Guyen L, Thulliez P, Gagelin B, Dufier JL. Congenital toxoplasmosis acquired from an immune woman. Pediatr Infect Dis J. 1997;16(1):75–7.

    CAS  Article  Google Scholar 

  77. 77.

    Dollfus H, Dureau P, Hennequin C, Uteza Y, Bron A, Dufier JL. Congenital toxoplasma chorioretinitis transmitted by preconceptionally immune women. Br J Ophthalmol. 1998;82(12):1444–5.,1998.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  78. 78.

    Claudio S, Rosane F, Cristina M, Robert N, Rubens B. Toxoplamosis transmitted to a newborn from the mother infected 20 years earlier. Am J Ophthalmol. 2003;136(2):370–1.

    Article  Google Scholar 

  79. 79.

    Howe DK, Sibley LD. Toxoplasma gondii comprises three clonal lineages: correlation of parasite genotype with human disease. J Infect Dis. 1995;172(6):1561–6.

    CAS  Article  PubMed  Google Scholar 

  80. 80.

    Arranz-Solis D, Cordeiro C, Young LH, Darde ML, Commodaro AG, Grigg ME, Saeij JPJ. Serotyping of Toxoplasma gondii infection using peptide membrane arrays. Front Cell Infect Microbiol. 2019.

    Article  PubMed  PubMed Central  Google Scholar 

  81. 81.

    Chiebao DP, Pena HF, Passarelli D, Santin T, Pulz LH, Strefezzi RF, Seva AP, Martins CM, Lopes EG, Filho JHHG, Gennari SM, Moares RM. Congenital transmission of Toxoplasma gondii after experimental reinfection with Brazilian typical strains in chronically infected sheep. Front Vet Sci. 2019;6:93. (eCollection 2019).

    Article  PubMed  PubMed Central  Google Scholar 

  82. 82.

    Elbez-Rubinstein A, Ajzenberg D, Dardé ML, Cohen R, Dumètre A, Yera H, Gondon E, Janaud JC, Thulliez P. Congenital toxoplasmosis and reinfection during pregnancy: case report, strain characterization, experimental model of reinfection, and review. J Infect Dis. 2009;199(2):280–5.

    Article  PubMed  Google Scholar 

  83. 83.

    Dzitko K, Staczek P, Gatkowska J, Dlugonska H. Toxoplasma gondii: serological recognition of reinfection. Exp Parasitol. 2006;112(2):134–7. (Epub 2005 Nov 14).

    CAS  Article  PubMed  Google Scholar 

  84. 84.

    Dao A, Fortier B, Soete M, Plenat F, Dubremetz JF. Successful reinfection of chronically infected mice by a different Toxoplasma gondii genotype. Int J Parasitol. 2001;31(1):63–5.

    CAS  Article  PubMed  Google Scholar 

  85. 85.

    Araujo F, Slifer T, Kim S. Chronic infection with Toxoplasma gondii does not prevent acute disease or colonization of the brain with tissue cysts following reinfection with different strains of the parasite. J Parasitol. 1997;83(3):521–2.

    CAS  Article  Google Scholar 

  86. 86.

    Franco PS, da Silva NM, de Barbosa BF, de Gomes AO, Ietta F, Shwab EK, Su C, Mineo JR, Ferro EAV. Calomys callosus chronically infected by Toxoplasma gondii clonal type II strain and reinfected by Brazilian strains is not able to prevent vertical transmission. Front Microbiol. 2015;6:181. (eCollection 2015).

    Article  PubMed  PubMed Central  Google Scholar 

  87. 87.

    Alvarado-Esquivel C, Liesenfeld O, Márquez-Conde JA, Estrada-Martínez S, Dubey JP. Seroepidemiology of infection with Toxoplasma gondii in workers occupationally exposed to water, sewage, and soil in Durango, Mexico. J Parasitol. 2010;96(5):847–50. (Epub 2010 Jun 17).

    CAS  Article  PubMed  Google Scholar 

  88. 88.

    Shapiro K, Bahia-Oliveira L, Dixon B, Dumetre A, de Wit LA, VanWormer E, Villena I. Environmental transmission of Toxoplasma gondii: oocysts in water, soil and food. Food Waterborne Parasitol. 2019;15:e00049.

    Article  PubMed  PubMed Central  Google Scholar 

  89. 89.

    Zhou Q, Wang Q, Shen H, Zhang Y, Zhang S, Li X, Acharya G. Seroepidemiological map of Toxoplasma gondii infection and associated risk factors in preconception period in china: a nationwide cross-sectional study. J Obstet Gynaecol Res. 2018;44(6):1134–9. (Epub 2018 Apr 19).

    CAS  Article  PubMed  Google Scholar 

  90. 90.

    Desmonts G, Couvreur J, Thulliez P. Congenital toxoplasmosis. 5 cases of mother-to-child transmission of pre-pregnancy infection. Presse Med. 1990;19(31):1445–9.

    CAS  PubMed  Google Scholar 

  91. 91.

    Gláucia MQA, Vasconcelos-Santos DV, Carellos EVM, Romanelli RMC, Vitor RWA, Carneiro ACAV, Januario JN. Congenital toxoplasmosis from a chronically infected woman with reactivation of retinochoroiditis during pregnancy. J Pediatr (Rio J). 2009;86(1):85–8. (Epub 2009 Nov 16).

    Article  Google Scholar 

  92. 92.

    Greigert V, Pfaff AW, Sauer A, Filisetti D, Candolfi E, Villard O. Biological diagnosis of ocular toxoplasmosis: a nine-year retrospective observational study. mSphere. 2019;4(5):00636–719.

    Article  Google Scholar 

  93. 93.

    Villard O, Cimon B, L’Ollivier C, Fricker-Hidalgo H, Godineau N, Houze S, Paris L, Pelloux H, Villena I, Candolfi E. Serological diagnosis of Toxoplasma gondii infection: recommendations from the French National Reference Center for Toxoplasmosis. Diagn Microbiol Infect Dis. 2016;84(1):22–33. (Epub 2015 Sep 1).

    CAS  Article  PubMed  Google Scholar 

  94. 94.

    Hegab SM, Al-Mutawa SA. Immunopathogenesis of toxoplasmosis. Clin Exp Med. 2003;3(2):84–105.

    CAS  Article  PubMed  Google Scholar 

  95. 95.

    Sensini A. Toxoplasma gondii infection in pregnancy: opportunities and pitfalls of serological diagnosis. Clin Microbiol Infect. 2006;12(6):504–12.

    CAS  Article  PubMed  Google Scholar 

  96. 96.

    Hashiguchi J, Onozawa M, Naka T, Hatanaka KC, Shiratori S, Sugita J, Fujimoto K, Matsuno Y, Teshima T. Re-infection of Toxoplasma gondii after HSCT presenting lymphadenopathy resembling recurrence of lymphoma. Transpl Infect Dis. 2018;20(3):12892.

    Article  Google Scholar 

  97. 97.

    Saso A, Bamford A, Grewal K, Noori M, Hatcher J, D’Arco F, Guy E, Lyall H. Fifteen-minute consultation: management of the infant born to a mother with toxoplasmosis in pregnancy. Arch Dis Child Educ Pract Ed. 2020;105(5):262–9.

    Article  Google Scholar 

  98. 98.

    Liang L, Dökaya M, Juarez S, Caner A, Jasinskas A, Tan X, Hajagos BE, Bradley PJ, Korkmaz M, Gürüz Y, Felgner PL, Davies DH. Identification of potential serodiagnostic and subunit vaccine antigens by antibody profiling of toxoplasmosis cases in Turkey. Mol Cell Proteom. 2011;10(7):M110.006916.

    CAS  Article  Google Scholar 

  99. 99.

    Kong JT, Grigg ME, Uyetake L, Parmley S, Boothroyd JC. Serotyping of Toxoplasma gondii infections in humans using synthetic peptides. J Infect Dis. 2003;187(9):1484–95. (Epub 2003 Apr 15).

    CAS  Article  PubMed  Google Scholar 

  100. 100.

    Xiao J, Buka SL, Cannon TD, Suzuki Y, Viscidi RP, Torrey EF, Yolken RH. Serological pattern consistent with infection with type I Toxoplasma gondii in mothers and risk of psychosis among adult offspring. Microbes Infect. 2009;11(13):1011–8. (Epub 2009 Jul 26).

    CAS  Article  PubMed  Google Scholar 

  101. 101.

    Sun X, Huijun Lu, Jia B, Chang Z, Peng S, Yin J, Chen Q, Jiang N. A comparative study of Toxoplasma gondii seroprevalence in three healthy Chinese populations detected using native and recombinant antigens. Parasit Vectors. 2013;6(1):241.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  102. 102.

    Appleford PJ, Smith JE. Strain and stage specific variation in Toxoplasma gondii antigens. Int J Parasitol. 2000;30(11):1187–91.

    CAS  Article  Google Scholar 

  103. 103.

    Kasper LH, Ware PL. Recognition and characterization of stage-specific oocyst/sporozoite antigens of Toxoplasma gondii by human antisera. J Clin Invest. 1985;75:1570.

    CAS  Article  Google Scholar 

  104. 104.

    Santana SS, Gebrim LC, Carvalho FR, Barros HS, Barros PC, Pajuaba ACAM, Messina V, Possenti A, Cherchi S, Reiche EMV, Navarro IT, Garcia JL, Pozio E, Mineo TWP, Spano F, Mineo JR. CCp5A protein from Toxoplasma gondii as a serological marker of oocyst-driven infections in humans and domestic animals. Front Microbiol. 2015;24(6):1305. (eCollection 2015).

    Article  Google Scholar 

Download references


The authors thank Dr. Hiroshi Arai (neurologist) for taking care of the patient and providing clinical information.


There are no funding details to be declared.

Author information




YO, HF, TN KI, FT, NI, HK, and RM evaluated the patient clinically, and revised the manuscript. KU managed clinical samples. NI made the ophthalmological diagnosis and cared for the patient. HK made the pathological diagnosis and contributed microscopic pictures. YO reviewed the literature and prepared the manuscript. RM provided substantial contributions to the design of the manuscript, revising it critically for important intellectual content, and obtained final approval of the version to be published. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Yoshihiro Oya.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Written informed consent was obtained from the patient for publication of this article. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests


Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Oya, Y., Futami, H., Nakazawa, T. et al. Tubulointerstitial nephritis and uveitis syndrome following meningitis and systemic lymphadenopathy with persistent Toxoplasma immunoglobulin M: a case report. J Med Case Reports 15, 482 (2021).

Download citation


  • Persistent immunoglobulin M (IgM)
  • Drug-induced lymphocyte stimulation test (DLST)
  • Lymphocyte transformation test (LTT)
  • Tubulointerstitial nephritis and uveitis (TINU) syndrome
  • Toxoplasma gondii
  • IgG avidity test
  • Strain-specific diagnosis
  • Meningitis